MEMPHIS, Tenn.--(BUSINESS WIRE)--Jun. 22, 2012--
GTx, Inc. (Nasdaq: GTXI) announced today that it is sponsoring at the
MASCC/ISOO 2012 International Symposium, a panel presentation on “Muscle
Wasting in Non-Small Cell Lung Cancer Patients: A New Scientific
Approach to Management.” The panel presentation will be held on June 29,
2012, from 5:30 to 7:00pm in Hall A of the Hilton New York Hotel in New
York, New York. Speakers will include Dr. Jeffrey Crawford, Chief,
Division of Medical Oncology at Duke University, Dr. James T. Dalton,
VP, Chief Scientific Officer at GTx, Inc., Dr. Richard J. Gralla,
Medical Director, Quality of Life Research Associates, Dr. Carla Prado,
Assistant Professor, Florida State University, and Bonnie J. Addario,
President, Founder and Chair of the Bonnie J. Addario Lung Cancer
Foundation.
About GTx
GTx, Inc., headquartered in Memphis, Tenn., is a biopharmaceutical
company dedicated to the discovery, development and commercialization of
small molecules that selectively target hormone pathways for the
treatment of cancer, cancer supportive care and other serious medical
conditions. GTx is conducting two pivotal Phase III clinical trials in
the United States, Europe and South America, evaluating a once daily 3
mg dose of enobosarm, a selective androgen receptor modulator, for the
prevention and treatment of muscle wasting in patients with non-small
cell lung cancer. More information about these two clinical studies can
be found at www.gtxclinicaltrials.com.
Source: GTx, Inc.
GTx, Inc.
Marc Hanover, President, 901-523-9700
Print Page
E-mail Page
RSS Feeds
E-mail Alerts
IR Contacts
Financial Tear Sheet
